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Background: Patient satisfaction with remote patient monitoring (RPM) of implantable car-
dioverter defibrillators (ICDs) seems to be high, yet knowledge on long-term patient experiences
is limited. The European REMOTE-CIED study explored patients' experiences with RPM, exam-
ined patient's preferences for ICD follow-up, and identified determinants of patient's preferences
in the first 2 years postimplantation.
Methods: European heart failure patients (N = 300; median age = 66 years [interquartile range
(IQR)=59-73], and22% female)with a first-time ICDreceived aBostonScientific LATITUDERPM
system (Marlborough,MA, USA) and had scheduled in-clinic follow-ups once a year. Patients com-
pleted questionnaires at 1-2weeks and also at 3, 6, 12, and 24months postimplantation and clini-
cal datawere obtained from theirmedical records. Patient evaluation datawere analyzed descrip-
tively, and Student's t-tests/Man-Whitney U tests or Chi-square tests/Fisher's exact tests were
performed to examine determinants of patient preferences.
Results: At 2 years postimplantation, the median patient satisfaction score with the RPM sys-
tem was 9 out of 10 (IQR = 8-10), despite 53% of the patients experiencing issues (eg, failure
to transmit data). Of the 221 patients who reported their follow-up preferences, 43% preferred
RPM and 19% preferred in-clinic follow-up. Patients with a preference for RPMwere more likely
to be higher educated (P= 0.04), employed (P= 0.04), and equipped with a new LATITUDEmodel
(P= 0.04), but less likely to suffer from chronic obstructive pulmonary disease (P= 0.009).
Conclusion: In general, patients were highly satisfied with RPM, but a subgroup preferred in-
clinic follow-up. Therefore, physicians should include patients’ concerns and preferences in the
decision-making process, to tailor device follow-up to individual patients’ needs and preferences.
K EYWORDS
implantable cardioverter defibrillator, patient experiences, patient preferences, remote patient
monitoring
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1 INTRODUCTION
Patients who are at high risk for life-threatening ventricular arrhyth-
mias are preferably treated with an implantable cardioverter defibril-
lator (ICD). The number of ICD patients has increased due to expand-
ing indications,1 leading to higher workload and increased healthcare
costs.2 Remote patient monitoring (RPM) systems can send disease-
and ICD-related data from the patient's home to the hospital, and are,
therefore, a promising alternative to in-clinic follow-up.3
Two meta-analyses in ICD patients have shown that RPM is at
least comparable to in-clinic follow-up with regard to the clinical
outcomes,4,5 and it might be cost effective.4 Despite this support-
ing evidence, and its inclusion in consensus guidelines from the Euro-
pean Society of Cardiology6 and the Heart Rhythm Society,7 RPM is
not yet a standard practice. The American PREDICT-RM registry indi-
cated that only 62%of thenewly implantedRPM-capable deviceswere
enrolled on RPM,8 probably due to reimbursement issues and hospital
policy.9 In addition, patient participationwas suboptimal, as 24%of the
enrolled patients did not activate their RPM system at home. Younger
age, racial and ethnic minorities, having no health insurance, shorter
travel distance to the hospital, and the presence of comorbidities or
procedure-related adverse events were associated with a lower like-
lihood of RPM activation.8
Most studies do indicate that ICD patients are generally satisfied
with RPM, mostly appreciating the convenience of the fewer hospi-
tal visits and the reassurance of being monitored.10–20 Nevertheless,
there seems to be a subgroup (5%-22%) that does not feel comfortable
with RPM,14,18 and reports a strong preference for in-clinic follow-
up.12,15,21 Two studies showed that low satisfaction with RPM was
associated with anxiety for technology, less comprehension of RPM,16
and not being treatedwith cardiac resynchronization therapy (CRT).17
However, nearly all studies measured RPM experiences using single-
item purpose-designed questions, and do not report study refusals or
dropouts due to patient preferences. Moreover, most studies had a
1 year of follow-up, which seems to be too short as patients are still
recovering in the first year after implantation, and generally only miss
one in-office visit compared to standard in-clinic follow-up.22
Better insight into patient experiences with RPM could support
its implementation in standard practice, especially since patients’ atti-
tudes and perceptions of RPM may influence monitoring quality and
outcomes.23 Therefore, the European REMOTE-CIED study is the first
to examine patient evaluations of RPM in the first 2 years after ICD
implantation, using Boston Scientific's LATITUDE system (Boston Sci-
entific, Marlborough, MA, USA), including blood pressure cuffs and
weighing scale for heart failure monitoring.
2 METHODS
2.1 Study design and participants
The study sample consisted of 300 European patients with heart fail-
ure and an ICD, participating in the REMOTE-CIED study and random-
ized to the RPM group. The in-clinic group (n = 298) was not included
in this study, as these patients did not receive an RPM system and,
therefore, could not evaluate it. The REMOTE-CIED study was pri-
marily designed to examine the influence of RPM on patient-reported
outcomes.24 Patients were recruited from 32 general and academic
hospitals in France, Germany, the Netherlands, Spain, and Switzerland
between April 2013 and January 2016. Inclusion criteria were symp-
tomatic heart failure (ie, left ventricular ejection fraction [LVEF]≤35%
and New York Heart Association [NYHA] functional class II or III) and
a first-time Boston Scientific ICD (single- or dual-chamber) or CRT-
defibrillator (CRT-D). Patients less than 18 or more than 85 years of
age, patients on thewaiting list for heart transplantation, patientswith
a psychiatric history other than affective or anxiety disorders, as well
as patients who were unable to complete questionnaires due to cogni-
tive impairment or language problems, were excluded.
Patients randomized into the RPM arm received a Boston Scientific
LATITUDE RPM system, including blood pressure cuffs and a weigh-
ing scale (ie, model number 6288, 6290, or 6468), during their first in-
clinic checkup at 4-8 weeks after implantation. During this visit, they
were instructed on how to install and use the system by the hospital
staff, and additionally received an instruction manual and installation
DVDtouse at home. Thereafter, they had a scheduled in-clinic checkup
once a year, as most other checkups were performed remotely.24 The
REMOTE-CIED study was conducted in accordance with the Declara-
tion of Helsinki, and the medical ethics committees of all participat-
ing centers approved the study protocol. All patients received oral and
written information about the study during their hospitalization for
ICD implantation and providedwritten informed consent.
2.2 Materials
All patients participating in the REMOTE-CIED study completed a
set of language-specific questionnaires at 1-2 weeks postimplantation
(baseline), and at 3, 6, 12, and 24months postimplantation.
The patients in the RPM group completed a 28-item purpose-
designed questionnaire about the RPM system at 3, 6, 12, and 24
months after implantation (Table 1). Patients were classified as having
a preference for RPMor in-clinic follow-up if they reported this prefer-
ence in the 24-month follow-up questionnaire, or if they switched the
studyarm (ie, RPMto in-clinic or in-clinic toRPM)on their ownrequest.
Patients’ satisfaction with cardiologic care, in general, was mea-
sured at 24-month follow-upusing a visual analogue scale ranging from
0 to 100, with higher scores indicating higher levels of satisfaction.
Information on sociodemographic characteristics was collected
using purpose-designed questions in the baseline questionnaire, and
it included age, sex, marital status (single vs having a partner), educa-
tional level (secondary school or lower vs tertiary school or higher), and
employment status (currently employed vs unemployed).
Information on patients’ clinical characteristicswas obtained from
their medical records at the baseline, and was recorded into an elec-
tronic case report form by local investigators at the participating cen-
ters. It included information on type of device (single- or dual-chamber
ICD, or CRT-D), indication for ICD (primary vs secondary), NYHA
functional class, heart failure etiology (ischemic vs nonischemic), QRS
duration, LVEF assessed within 3 months prior to implantation, and
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TABLE 1 Outcomes on purpose-designed questionnaire for patient evaluation of RPMusing the LATITUDE systema
Item Question 0 1 2 3
1 Are you satisfied with the explanation of the LATITUDE system by the
hospital? b(0 “very unsatisfied” to 3 “very satisfied”)
5% 8% 55% 32%
2 The installation DVD helpedmewith the installation of the LATITUDE
system b(0 “strongly disagree” to 3 “strongly agree”)
22% 23% 44% 11%
3 The information in the instructionmanual is clear enough b(0 “strongly
disagree” to 3 “strongly agree”)
1% 7% 73% 19%
4 How do you experience the ease of use of the LATITUDE system? (0 “very
negative” to 3 “very positive”)
0% 1% 58% 41%
5 I trust that my personal data are handled correctly by the LATITUDE
system (0 “strongly disagree” to 3 “strongly agree”)
1% 2% 64% 33%
6 Have you experienced any problems for which you needed to contact the
hospital and/or Boston Scientific? (0 “no” or 1 “yes”)
47% 53% - -
7 If yes, what problems have you faced? (open ended) – - - -
8 If yes, how satisfied were youwith the help you have received? (0 “very
unsatisfied” to 3 “very satisfied”)
9% 7% 50% 34%
9 Are the problems solved? (0 “no” or 1 “yes”) 15% 85% - -
10 The LATITUDE system providesmewith a feeling of security (0 “strongly
disagree” to 3 “strongly agree”)
1% 3% 62% 34%
11 Does the LATITUDE system influence your daily functioning? (0 “negative
influence”; 1 “no influence”; 2 “positive influence”)
2% 69% 29% -
12 If yes, please explain (open ended) - - - -
13 Daily weighmoments are a burden tome (0 “strongly disagree” to 3
“strongly agree”)
27% 50% 17% 6%
14 I find it bothersome tomeasuremy blood pressure regularly (0 “strongly
disagree” to 3 “strongly agree”)
32% 57% 7% 4%
15 Because of LATITUDE, I ammore aware of my own health status (0
“strongly disagree” to 3 “strongly agree”)
4% 9% 73% 14%
16 Because of LATITUDE, I tend to adheremore to given health advice (0
“strongly disagree” to 3 “strongly agree”)
1% 30% 62% 7%
17 It is an advantage that I visit the hospital less often because of LATITUDE
(0 “strongly disagree” to 3 “strongly agree”)
0% 6% 59% 35%
18 Do you experience any disadvantages of the LATITUDE system? (0 “no” or
1 “yes”)
95% 5% - -
19 If yes, please explain (open ended) - - - -
20 The LATITUDE device remindsme of my illness and/or ICD/CRT-D (0
“strongly disagree” to 3 “strongly agree”)
11% 41% 44% 4%
21 The LATITUDE system improves care for people living with an ICD (0
“strongly disagree” to 3 “strongly agree”)
0% 2% 75% 23%
22 Are you satisfied with the number of hospital visits or would you like to
visit the hospital more/less often? (0 “less often”; 1 “satisfied”; 2 “more
often”)
3% 87% 10% -
23 Do you prefer follow-up at the hospital or through LATITUDE system? (0
“hospital”; 1 “no preference”; 2 “Latitude system”)
19% 38% 43% -
24 Please explain why you have this preference (open ended) - - - -
25 Do youwish to continue using the LATITUDE system in the future? (0
“no”; 1 “not sure”; 2 “yes”)
3% 13% 84% -
26 Would you recommend LATITUDE to other patients with an ICD? (0 “no”
or 1 “yes”)
3% 97% - -
27 On a scale from 1 to 10, how satisfied are youwith LATITUDE? (0 “0-5:
unsatisfied”; 1 “6-10: satisfied”)
3% 97% - -
28 Do you have any additional remarks about the LATITUDE system? (open
ended)
- - - -
aQuestionnaire specifically refers to LATITUDE system, to make sure that patients understand that this questionnaire is about their RPM system (“LATI-
TUDE” is printed on their RPM transmitter); bAssessed at 3months after ICD implantation, all other items are assessed at 24months postimplantation.
ICD= implantable cardioverter-defibrillator; RPM= remote patient monitoring.
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comorbidities (diabetes mellitus, chronic obstructive pulmonary
disease [COPD], renal disease, atrial fibrillation, hypertension,
and anemia). Clinical outcome measures included the number of
(un)scheduled cardiac-related in-clinic or telephone consultations (ie,
continuous totals), cardiac-related emergency room visits (ie, 0 “no”
and ≥1 “yes”), cardiac-related hospital admissions (ie, 0 “no” and ≥1
“yes”), and ICD shocks (ie, 0 “no” and ≥1 “yes”) during the follow-up
period. These data were collected from patients’ medical records,
classified and entered into an electronic case report form by the local
hospital staff.
Patients’ lifestyle characteristics, including bodymass index, smok-
ing status (ie, no/yes, number of cigarettes per day), alcohol use (ie,
no/yes, number of consumptions per week), and attendance to cardiac
rehabilitation (ie, are you participating in a cardiac rehabilitation pro-
gram?), were collected in the baseline questionnaire. Additionally, self-
care behavior was measured using the validated 12-item European
Heart Failure Self-care Behavior Scale.25
Psychological characteristics were collected using question-
naires at the baseline and included information on use of psy-
chotropic medication or treatment for psychological problems; heart
failure-specific health status (23-item Kansas City Cardiomyopa-
thy Questionnaire26); anxiety and depressive symptoms (7-item
Generalized Anxiety Disorder Scale, and the 9-item Patient Health
Questionnaire, respectively27,28); Type D personality (14-item Type
D Scale29); heart failure perceptions (9-item brief Illness Perception
Questionnaire30); ICD acceptance (12-item Florida Patient Accep-
tance Scale31,32); and ICD-related concerns (8-item ICD Patient
Concerns Questionnaire33,34). Regarding the two last mentioned
questionnaires, a forward-backward translation procedure was per-
formed for the German, French, and Spanish version. In all other cases,
we used the official and validated language-specific questionnaires. A
detailed description of these questionnaires was published before.35
Previously reported Chronbach's alphas of these questionnaires in the
current sample ranged from 0.69 to 0.98, and thereby indicate good
levels of internal consistency.36
2.3 Statistical analyses
According to the study protocol, multivariable logistic and linear
regression analyses would be performed to examine which fac-
tors were independently associated with satisfaction with RPM
as a dichotomous outcome (satisfied: ≥6 “yes,”< 6 “no”), and as a
continuous outcome (satisfied: 0-10), respectively.24 Yet, the satis-
faction with RPM score was extremely skewed to the right, with only
seven patients reporting a satisfaction score of <6 at 2 years after
implantation. Therefore, we decided that patient preferences for
follow-up would be a meaningful substitute outcome measure. The
baseline characteristics and clinical outcomes were reported for the
total sample, and for patients with a preference for RPM or in-clinic
follow-up. For categorical and continuous variables, we reported
frequencies with percentages and means with standard deviation (or
medians with interquartile range [IQR] if appropriate), respectively.
Student's t-tests and Chi-square tests (or Mann-Whitney U tests and
Fisher's exact tests if appropriate) were performed to examine which
sociodemographic, clinical, and psychological characteristics were
associated with preference for follow-up, and to explore associations
between patient preferences and clinical outcomes. Other patient
evaluation data of the LATITUDE RPM system were analyzed descrip-
tively. All tests were two-tailed, and a P value of <0.05 was used to
indicate statistical significance. All analyses were performed using
SPSS 22.0 forWindows (IBMCorp., Armonk, NY, USA).
3 RESULTS
3.1 Baseline characteristics
In total, 595patients participated in theREMOTE-CIEDstudy, ofwhich
300 patients were randomized into the RPM group and evaluated the
LATITUDE RPM system. Of these 300 patients, 161 were enrolled in
the Netherlands, 66 in Germany, 50 in France, 16 in Spain, and seven
in Switzerland. The majority of the patients (78%) received a new LAT-
ITUDE RPM model (ie, 6288 or 6290). The baseline characteristics of
the sample are shown in Table 2.
During the 2-year follow-up, there were 50 crossovers in the total
sample (ie, 16 from the RPM to in-clinic group and 34 from the in-
clinic to RPM group). Reasons for crossover from RPM to in-clinic
included patient request (n = 7), technical issues with the RPM sys-
tem (n = 5), and noncompliance/RPM not handed out by mistake
(n = 4). Reasons for crossover from in-clinic to RPM included patient
request (n = 7), long travel distance (ie, >1.5 h, n = 16), and by
physicians’ choice (n = 11). According to the intention-to-treat prin-
ciple, patients received questionnaires belonging to their randomiza-
tion group regardless of crossover. As a result, we do not have evalua-
tions of the RPM system from the 33 patients who switched from the
in-clinic to RPM group.
3.2 Patient evaluations of the RPM system
As patient evaluations of the RPM system were stable over time, we
only reported the 2-year follow-up data.
3.2.1 Installation and usability
Almost all patients were satisfied with the information on the RPM
system that they received from their healthcare professional (87%),
and reported to understand the information in the instruction manual
(91%). For 55% of the patients, the included installation DVD was
helpful during installation. However, during the first 2 years after
implantation, 53% of the patients experienced issues with the system
for which they had to contact their hospital or the Boston Scientific
helpdesk. Most issues occurred in the first months, as 34% of the
participants already reported issues at 6 months postimplantation
(ie, 4-5 months after receiving RPM). Many of these issues concerned
problems with installation. For example, patients reported that they
did not receive sufficient information or an installation DVD. Some
patients also reported to feel insecure about the RPM system, where-
upon they contacted the hospital for reassurance (eg, to check if data
were transmitted correctly). Over the complete 2-year follow-up,
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(N= 43) P value
Sociodemographic characteristics
Age 66 (59-73) 66 (56-73) 67 (60-74) 0.57
Female 67 (22%) 17 (18%) 10 (23%) 0.48
Having a partner 222 (74%) 71 (76%) 32 (74%) 0.89
High educational level
(tertiary)
168 (56%) 59 (63%) 19 (44%) 0.04
Employed 60 (20%) 26 (28%) 5 (12%) 0.04
Clinical characteristics
New LATITUDEmodelb 218 (78%) 77 (84%) 27 (68%) 0.04
LATITUDEmodel with GSM
modulec
39 (14%) 16 (17%) 6 (15%) 0.74
Transmission problems during
follow-upd
103 (53%) 37 (53%) 12 (41%) 0.30
Cardiac resynchronization
therapy
114 (38%) 37 (39%) 13 (30%) 0.30
Primary prophylactic ICD
indication
258 (86%) 84 (89%) 37 (86%) 0.58
Ischemic heart failure
etiology
158 (53%) 50 (53%) 22 (52%) 0.83





Ejection fraction 27 (22-31) 26 (20-31) 28 (26-31) 0.15
NewYork Heart Association
class III
98 (33%) 27 (29%) 15 (35%) 0.47
Poor health statuse 91 (31%) 23 (25%) 13 (30%) 0.52
Diabetes mellitus 90 (30%) 27 (29%) 16 (37%) 0.32
Chronic obstructive
pulmonary disease
45 (15%) 7 (7%) 10 (23%) 0.009
Renal disease 75 (25%) 24 (26%) 11 (26%) 0.99
History of atrial fibrillation 85 (28%) 25 (27%) 14 (33%) 0.47
Hypertension 171 (57%) 55 (59%) 24 (56%) 0.77
Anemia 29 (10%) 8 (9%) 5 (12%) 0.56
Lifestyle characteristics
Bodymass index> 30 68 (23%) 20 (21%) 10 (23%) 0.80
Smoking 48 (16%) 10 (11%) 9 (21%) 0.11
Use of alcohol 144 (48%) 48 (52%) 20 (47%) 0.54
Self-care behaviorf 25 (20-33) 24 (18-33) 26 (20-30) 0.95
Cardiac rehabilitation 58 (20%) 17 (19%) 10 (24%) 0.53
Psychological characteristics
Type D personalityg 61 (21%) 18 (20%) 7 (17%) 0.67
Anxietyh 37 (13%) 7 (8%) 5 (12%) 0.41
Depressioni 48 (16%) 15 (17%) 5 (12%) 0.46
Illness perceptionsj 40 (30-47) 40 (29-47) 39 (31-47) 0.82
ICD concernsk 8 (3-15) 9 (3-13) 7 (3-19) 0.89
Device acceptancel 66 (56-73) 67 (56-75) 65 (54-75) 0.58
Psychotropic medicationm 48 (16%) 11 (12%) 7 (16%) 0.48
(Continues)








(N= 43) P value
Psychological treatment 12 (4%) 4 (4%) 1 (2%) 0.58
Travel distance to hospital
(min)
30 (20-45) 30 (20-45) 25 (15-38) 0.10
Results presented asN (%) for categorical variables and asmedian (interquartile range) for continuous variables. Significant results are presented in bold.
aBased on 221 patients (79missing); bNew LATITUDEmodel: patient receivedmodel number 6288 or 6290, instead of oldmodel number 6468; cLATITUDE
model with GSMmodule: patients received model number 6288; dTransmission problems during follow-up: yes/no (105 missing); ePoor health status: total
score Kansas City Cardiomyopathy Questionnaire < 50; fSelf-care behavior: total score European Heart Failure Self-Care Behavior Scale; gType D person-
ality: score of ≥10 on both negative affectivity and social inhibition subscales of Type D scale; hAnxiety: total score of ≥10 on Generalized Anxiety Ques-
tionnaire; iDepression: total score of ≥10 on Patient Health Questionnaire; jIllness perceptions: total score brief Illness Perceptions Questionnaire; kICD
concerns: total score on ICD Concerns Scale; lDevice acceptance: total score on Florida Patient Acceptance Scale; mPsychotropic medication: antidepres-
sants, anxiolytics, and/or hypnotics.
ICD= implantable cardioverter-defibrillator; RPM= remote patient monitoring.
most reported issues concerned connection problems resulting in data
transmission failure (ie, between LATITUDE system and hospital, or
between blood pressure cuffs/weighing scale and LATITUDE system).
In total, 85% of all the reported issues were solved, and in 84% of the
cases, patients were satisfied with the help they received from their
hospital or the Boston Scientific helpdesk to solve their issues. At 2
years postimplantation, 99% of the patients reported that the system
waseasy touse, 98%reported tohave confidence in personal data han-
dling, and 96% reported that the system provided themwith a sense of
security.
For the majority of the patients (69%), the RPM system did not
influence their daily functioning, while 30% of the patients experi-
enced apositive influence (eg, reassurance, better awareness of health,
less traveling, and fewer hospital visits), and 1% reported a negative
influence on their daily functioning (eg, privacy concerns or concerns
about bloodpressure results). For 48%of thepatients, theRPMsystem
reminded them of their illness and/or ICD, and themajority of patients
reported that it improved the awareness of their own health (87%) and
their adherence to given health advice (69%).
3.2.2 Satisfaction
Patients in the RPM group were highly satisfied with the cardiologic
care that they received (median = 90/100 [IQR = 80-100]). Of note,
their satisfaction levels did not differ from satisfaction levels in the
in-clinic group at 24 months after implantation (median = 90/100
[IQR = 80-100]; P = 0.95). Patients rated the RPM system with a
median score of 9 out of 10 (IQR = 8-10), with patients suffering
from renal disease being more satisfied compared to patients with-
out renal disease (median = 90/100 [IQR = 80-100] for both groups;
means = 9.02 ± 0.94 vs 8.65 ± 1.25; P = 0.02) and patients on psy-
chotropic medicine being less satisfied than patients not using psy-
chotropicmedicine (median= 90/100 [IQR= 80-100] for both groups;
means = 8.45 ± 1.55 vs 8.80 ± 1.12; P = .02). All other sociode-
mographic, clinical, and psychological characteristics were not signif-
icantly associated with satisfaction levels. Nearly all patients (98%)
considered RPM to be an improvement of care for ICD patients.
Only a small subgroup, varying between 3% and 6% over time, rated
their satisfaction with a score of ≤5. Hence, almost all the patients
(97%) would recommend the system to other patients, and the major-
ity of them (84%) wished to continue using the RPM system in the
future.
Despite positive evaluations, some patients (±5%) reported down-
sides of the RPM system in an open-ended question during the follow-
up period. Missing feedback on transmission success (ie, affirmation
that data were correctly received by their hospital) and ICD func-
tioning (eg, using a digital patient portal) were most often mentioned.
Additionally, some patients reported trouble sleeping due to the sys-
tem's lights, and a few patients reported they have a feeling of “being
watched.”
3.2.3 Preference for follow-up
At 2 years postimplantation, 79 (26%) patients did not answer the
question on their preference for follow-up and were regarded as
missing. These patients were more likely to have NYHA class III versus
II (46% vs 28%; P = 0.005), to smoke (24% vs 13%, P = 0.03), and to
performworse self-care behavior (26 [24-34] vs 24 [18-31];P=0.008).
Additionally, they were more likely to have been admitted at least
once during follow-up (43% vs 27%; P = 0.009), but received fewer
hospital consultations (5 [3-9] vs 7 [5-10]; P = 0.03) compared with
patients who did report a preference (n = 221). Of the remaining 221
patients, 94 (43%) preferred RPM, 43 (19%) preferred in-clinic, and 84
(38%) reported to have no preference. Patients who reported to have
no preferencewere comparable to patients with a preference (ie, RPM
or in-clinic) on all the baseline characteristics and clinical outcome
measures (all Ps> 0.05).
Next, we compared patients with a preference for RPM to patients
withapreference for in-clinic follow-up.Results indicated thatpatients
with a preference for RPM were less likely to suffer from COPD (22%
vs 46%, P = 0.009), and more likely to be higher educated (49% vs
35%, P = 0.04), to work (57% vs 39%, P = 0.04), and to have received
the new LATITUDE model (84% vs 68%, P = 0.04), as compared to
patients with a preference for in-clinic follow-up (Table 2). There were
no associations between patients’ preference for follow-up and clinical
outcome measures (Table 3). Multivariable analyses were not per-
formed, considering the small sample size of the in-clinic preference
group.
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TABLE 3 Cardiac-related hospital visits, emergency room visits, hospitalizations, and shocks over the first 24months postimplantation, for the
total sample, and stratified between follow-up preferencea
Total sample (N= 300) RPMpreference (N= 94) In-clinic preference (N= 43) P value
Number of hospital consultationsb 6 (4-9) 6 (5-10) 7 (4-9) 0.90
≥One emergency room visit 44 (15%) 14 (15%) 4 (9%) 0.37
≥One hospital admission 94 (31%) 26 (28%) 10 (23%) 0.59
≥ICD shocks 27 (9%) 56 (6%) 5 (12%) 0.29
Results presented asN (%) for categorical variables and asmedian (interquartile range) for continuous variables.
aBased on 221 patients (79missing); bIncluding all cardiac-related (un)scheduled in-hospital or telephone consultations.
ICD= implantable cardioverter-defibrillator; RPM= remote patient monitoring.
Looking at country-specific data, the majority of German patients
preferred RPM follow-up (64%), 12% of them preferred in-clinic
follow-up, and 24% had no preference. Almost half of the French
patients preferred RPM (42%), 11% of them preferred in-clinic follow-
up, and 47% of them did not have a preference. With regard to Dutch
patients, 35% preferred RPM, 23% preferred in-clinic follow-up, and
42% had no preference. Preferences of Spanish and Swiss patients
were not analyzed separately due to small sample sizes.
Patient motivations to prefer RPM follow-up included continuous
monitoring (eg, immediate action if necessary, compared to hospital
follow-up as “snapshot”), reassurance, time savings (eg, less traveling to
hospital, no interferencewith daily activities), cost savings (eg, no costs
for public transport or petrol, no parking costs), independence, and
ease. On the other hand, motives to prefer in-clinic follow-up included
human contact with physicians (eg, to discuss their personal situation
and to ask questions), trust in physician (eg, visiting cardiologist ismore
reassuring than RPM system), short travel distance to hospital, and
negative experiences with the RPM system. Patients who had no pref-
erence often acknowledged benefits of RPM, while emphasizing that
hospital visits could never be fully replaced. Also, at 2 years postim-
plantation, 10% of the patients would like to go to the hospital more
often than once a year.
4 DISCUSSION
To the best of our knowledge, this was the first study to examine long-
term patient experiences with RPM, and to explore which sociodemo-
graphic, clinical, and psychological factors are associatedwith patients’
preferences for ICD follow-up. The findingsof this studyare in linewith
the findings of the previous studies with smaller sample sizes, shorter
follow-up periods, and different RPM systems,22 and underline that
most ICD and CRT-D patients are highly satisfied with RPM. Patients
rated the LATITUDE RPM system with a median score of 9 out of 10.
They perceived the system to be easy to use, trusted the handling of
their personal data, reported that the system provided them with a
sense of security, and felt that it improved their health awareness and
adherence to physicians’ health advices. Nearly all patients perceived
RPMasan improvementof care for ICDandCRT-Dpatients, andwould
recommend it to other patients.
However, similar to previous studies,12,14,15,18,21 a subgroup of
our sample (16%-19%) did not wish to continue RPM in the future,
reported a preference toward in-clinic follow-up (19%), or reported to
have no preference (38%). Furthermore, 15% of all the patients who
refused study participation were not willing to be randomized to RPM
follow-up (15%).37 Motives to prefer in-clinic follow-up were a need
for personal contact with physicians, short travel distance to the hos-
pital, and negative experiences with the RPM system. Patients with
a preference for in-clinic follow-up were more likely to be less edu-
cated, unemployed, to suffer from COPD, and to be equipped with an
older LATITUDE model. Cognitive abilities seem to play an essential
role in the use and maintenance of technological products,38 includ-
ing RPMsystems. Also, patientswho are unemployedmay find the reg-
ular in-clinic visits during office hours less bothersome compared to
patients with a job. The American ALTITUDE registry and PREDICT-
RM trials indicated that patients with comorbidities were less likely
to use RPM.8 However, in the current study, only COPD was posi-
tively associated with a preference for in-clinic follow-up. This could
possibly be explained by the fact that these patients, often suffering
from dyspnea, value visiting physicians who review both their heart
and lungs in order to get better insights in their symptoms. However,
the general tendency of patients with comorbidities preferring regular
follow-up underlines the importance to investigate the integration of
other deviceswithCIEDhardware to allow formonitoring of comorbid
conditions and a complete assessment of patient status.39 We did not
observe associations between patient preferences and cardiac-related
clinical outcomes (ie, hospital consultations, emergency room visits,
hospital admissions, and ICD shocks). Future studies with larger sam-
ple sizes and longer follow-up periods with more events are necessary
to reexamine this.
Patients who received a newer LATITUDE model (ie, 6288/6290)
were more likely to prefer RPM follow-up compared to patients who
received anoldermodel (ie, 6468). This is surprising, as thenewermod-
els no longer have a touch screen, allowing patients to see, for exam-
ple, if a transmission was successful. Missing feedback (eg, on trans-
mission success and device functioning) was one of the main issues
reported by the patients in our study. This is in line with a study by
Petersen et al,18 where 84% of the patients wanted to receive more
information about transmissions, and 21% wished for a faster reply.
While direct feedback on transmission success and device function-
ingmight enhance patient-centered care, it will have considerable con-
sequences for the workflow. In this real-world practice study, most
participating centers contacted patients to discuss RPM data only if
necessary, and therefore handled a “no news is good news” policy.
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Nevertheless, it would be valuable to explore options to share data
with patients, and it speaks for itself that this must happen in close
collaboration with them. Recent research indicates that patients gen-
erally hold positive attitudes toward using mobile applications to
review their own RPM data and that this may lead to improved
self-management and a drop in their cardiovascular risk.40 Patient-
centered continuous technological developments like these may fur-
ther enhance patient experiences with RPM.
In our study, 38% of the patients did not have a strong preference
for either RPM or in-clinic follow-up, and 10% stated that they would
like to go to the clinic more than once a year. Most of these patients
wanted to benefit from RPM, as well as regular personal contact with
their physician. This may be driven by patients’ concerns about the
depersonalization of healthcare, and about maintaining the relation-
ship with their physician.41 All the patients who are involved in the
study suffered from heart failure, which may lead to additional ques-
tions and concerns that patients want to discuss personally. A good
physician-patient relationship could enhance patients’ adherence,13
and patients aremore likely to use their RPMsystems if they discussed
the functions, benefits, and limitations of this technology with their
physician, especially in an early stage.41
In the current study, we observed that patients enrolled in the
Netherlands more often preferred in-clinic follow-up (23%) compared
to patients from Germany and France (12% and 11%, respectively).
This finding is of interest, although a clear explanation is missing.
Akar et al8 showed that patients in rural areas were more likely
to receive RPM from their physician, and subsequently observed a
distance-dependent increase in the likelihood of RPM activation. This
shows that travel distance may influence treatment decisions regard-
ing follow-up. Physicians in rural areas could be more inclined to opt
for RPM, as they may perceive greater benefits for patients.8 Despite
travel distances being shorter in the Netherlands compared to Ger-
many and France, our univariate analyses did not indicate an effect of
travel time on patient preferences for follow-up. This may be due to
relatively low travel times with little variation. However, the impact of
travel distance and costsmight be interesting for future studies to look
into.
Taken all together, although recent clinical ICD guidelines strongly
advise routine use of RPM for ICD follow-up and patient satisfac-
tion with RPM is high, it remains important that patients are well-
educated about the installation, possibilities, and limitations of the sys-
tem. Patients’ concerns and preferences regarding follow-up should
be considered in a shared decision-making process, especially when
a patient is less educated, unemployed, or suffers from a comorbid
disease. Also, future research is warranted on how RPM can help
to actively involve patients in managing their own health. A recent
overview of systematic reviews concluded that RPM of heart failure
data has no positive effect on patients’ disease awareness and self-
care.42 The effect of RPMon patients’ self-care behavior in our sample
will be discussed in a future article.
Finally, this study has some limitations that have to be acknowl-
edged. Patient preferences for follow-up and experiences with RPM
were only assessed in patients who were initially randomized to the
RPM group. As a result, we only have limited information on patients
who switched from in-clinic to RPMover time. Also, insights in patients
who received care as usual are limited. It would have been valuable
to gain more knowledge on their attitudes toward RPM and prefer-
ences for follow-up as well. The large number of missings on the pref-
erence question (26%) may have introduced attrition bias, as these
patients may be systematically different from the others.43 In this par-
ticular study they suffered from more severe heart failure symptoms,
performed worse self-care behavior, were more likely to be admit-
ted during follow-up, and received fewer hospital consultations. The
needs and preferences of this high-risk group deserve extra attention
in clinical practice. Furthermore, all participating hospitals performed
in-clinic follow-up according to their standard practice. Although these
visits generally consist of device interrogation with or without phys-
ical examination, they may have differed between centers. On a pos-
itive note, these between-center differences reflect real-world prac-
tice and enhance the environmental validity of this study. The number
of (un)scheduled RPM transmissions may have varied between cen-
ters as well. Unfortunately, information on these transmissions was
not collected, preventing us from examining the relationship between
RPM transmission frequency and patient satisfaction and preferences.
Results of the current study cannot automatically be generalized to
samples from other (non-European) countries, as there may be impor-
tant differences in race/ethnicity, comorbidities, healthcare access,
and satisfaction with healthcare, as well as to patients with other
types of cardiac electronic implantable devices. It would be interest-
ing for future studies to examine this. Finally, this study examined
the LATITUDE system from Boston Scientific, and the RPM question-
naire was designed to evaluate this system in particular, which may
limit the generalizability of our findings to other RPM systems. How-
ever, all previous studies reporting on patient experiences or satisfac-
tion with RPM focus on systems from Medtronic (Minneapolis, MN,
USA),10,12,17–21 Biotronik (Berlin, Germany),13–16 St. JudeMedical (St.
Paul,MN,USA),11 orBostonScientific (Marlborough,MA,USA)8 alone.
Despite the evident benefits of including systems frommultiple manu-
facturers, results from the REMOTE-CIED study are in line with these
previous studies on different systems and indicate that the majority of
patients are much satisfied with RPM, with only a small subgroup pre-
ferring regular follow-up.
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